PMID- 15159305
OWN - NLM
STAT- MEDLINE
DCOM- 20040907
LR  - 20151119
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 13
IP  - 5
DP  - 2004 May
TI  - Increased plasma levels of insulin-like growth factor 2 and insulin-like growth 
      factor binding protein 3 are associated with endometrial cancer risk.
PG  - 748-52
AB  - Circulating insulin-like growth factors (IGFs) and their binding proteins have 
      been associated with increased risk of breast, prostate, colon, and lung cancer. 
      To examine the association of IGFs and endometrial cancer risk, we measured the 
      plasma levels of IGF-1, IGF-2, and IGF binding protein 3 (IGFBP-3) by ELISA in 80 
      women with endometrial cancer and 80 age-matched control subjects with no history 
      of cancer. Mean plasma levels of IGF-2 were significantly higher in women with 
      cancer versus controls (670 ng/ml versus 380 ng/ml, P < 0.001). In contrast, 
      significantly lower mean plasma levels of IGF-1 (155 mg/ml versus 185 ng/ml, P < 
      0.01) and IGFBP-3 (1703 ng/ml versus 2170 ng/ml, P < 0.001) were observed among 
      cases compared to the control group. Women in the highest quartile of IGF-2 were 
      found to have 9.67 (95% confidence interval 3.29-28.43) times the risk of 
      endometrial cancer than women in the lowest quartiles. Women in the highest 
      quartile of IGFBP-3 were associated with a significantly decreased risk for 
      developing endometrial cancer (odds ratio = 0.23, 95% confidence interval 
      0.09-0.60). These data suggest that increased plasma levels of IGF-2 and 
      decreased levels of IGFBP-3 are associated with an increased risk of endometrial 
      cancer. Further validation of these results is needed to determine the potential 
      usefulness of risk assessment.
FAU - Oh, Jonathan C
AU  - Oh JC
AD  - The Department of Gynecological Oncology, The University of Texas M.D. Anderson 
      Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030,USA.
FAU - Wu, Weiguo
AU  - Wu W
FAU - Tortolero-Luna, Guillermo
AU  - Tortolero-Luna G
FAU - Broaddus, Russell
AU  - Broaddus R
FAU - Gershenson, David M
AU  - Gershenson DM
FAU - Burke, Thomas W
AU  - Burke TW
FAU - Schmandt, Rosemarie
AU  - Schmandt R
FAU - Lu, Karen H
AU  - Lu KH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
SB  - IM
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Confidence Intervals
MH  - Endometrial Neoplasms/*blood/*epidemiology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Insulin-Like Growth Factor Binding Protein 3/*blood
MH  - Insulin-Like Growth Factor II/*metabolism
MH  - Logistic Models
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - Odds Ratio
MH  - Prognosis
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - United States/epidemiology
EDAT- 2004/05/26 05:00
MHDA- 2004/09/08 05:00
CRDT- 2004/05/26 05:00
PHST- 2004/05/26 05:00 [pubmed]
PHST- 2004/09/08 05:00 [medline]
PHST- 2004/05/26 05:00 [entrez]
AID - 13/5/748 [pii]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):748-52.